Ting‐Tsung Chang - Concepedia

Author

Ting‐Tsung Chang

Also Known As

Chen‐Yi Wu, Malcolm C. Hoffman, T Chang, T T CHANG, T T Chang, T. T. Chang, T.-T. Chang, T.‐T. Chang, TING‐TSUNG CHANG, Ting-Tsung Chang

153

Publications

10.7K

Citations

H-Index

Concepts

All Affiliations

National Cheng Kung University National Cheng Kung University Hospital Taipei Veterans General Hospital National Taiwan University Hospital Kaohsiung Medical University

About

Ting‐Tsung Chang is an author at National Cheng Kung University specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	31	3.7K
2	Public Health	4	4	116
3	Health Sciences	2	2	412
4	Biochemistry	2	2	80
5	Natural Sciences	1	1	66

Ting‐Tsung Chang

Publications

10.3K

Citations

H-Index

Page 1

	Year	Citations
A One-Year Trial of Lamivudine for Chronic Hepatitis B Ching‐Lung Lai, Rong‐Nan Chien, Nancy W.Y. Leung, New England Journal of Medicine	1998	1.8K
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote, New England Journal of Medicine	2003	996
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote, Gastroenterology HepatologyViral HepatitisPharmacologyHepatitis BHepatitis	2006	882
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B Yun‐Fan Liaw, Nancy W.Y. Leung, Ting‐Tsung Chang, Gastroenterology Hepatitis DHepatologyViral HepatitisHepatitis BHepatitis	2000	695
Extended Lamivudine Treatment in Patients With Chronic Hepatitis B Enhances Hepatitis B E Antigen Seroconversion Rates: Results After 3 Years of Therapy Nancy W.Y. Leung, Ching‐Lung Lai, Ting‐Tsung Chang, Hepatology	2001	628
Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos, E. Jenny Heathcote, New England Journal of Medicine	2005	535
Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B Robert G. Gish, Anna S. Lok, Ting‐Tsung Chang, Gastroenterology VaccinationHepatologyViral HepatitisHepatitis BHepatitis	2007	369
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Josep M. Llovet, Masatoshi Kudo, Philippe Merle, The Lancet Oncology OncologyHepatologyMedicineClinical TrialsPembrolizumab Versus Lenvatinib	2023	364
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study Michael Manns, S. Pol, Ira M. Jacobson, The Lancet Multicohort StudyHepatitis CViral HepatitisAntiviral Drug DevelopmentAntiviral Therapy	2014	343
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease Yun‐Fan Liaw, I‐Shyan Sheen, Chuan–Mo Lee, Hepatology	2010	319

Page 1